Synergistic efficacy of Bisbenzimidazole and Carbonyl Cyanide 3-Chlorophenylhydrazone combination against MDR bacterial strains

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Sinha, Devapriya ^a   Pandey, Stuti ^a   Singh, Raja ^b   Tiwari, Vinod ^a   Sad, Kirti ^b   Tandon, Vibha ^a,b  

^a UNIVERSITY OF DELHI   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBONYL 3-CHLOROPHENYLHYDRAZONE; DNA TOPOISOMERASE; HYDRAZONE DERIVATIVE; PIBENZIMOL;

ANIMAL; BAGG ALBINO MOUSE; BIOFILM; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI K 12; FEMALE; GENE; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; NEUTROPENIA; PATHOLOGY; PSEUDOMONAS AERUGINOSA; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; BISBENZIMIDAZOLE; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI K12; FEMALE; GENE EXPRESSION; GENES, MDR; HYDRAZONES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; PSEUDOMONAS AERUGINOSA; THIGH;

EID: 85015450516     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44419     Document Type: Article

References (47)

1. Rice, L. B. The clinical consequences of antimicrobial resistance. CurrOpin. Microbiol. 12, 476-481 (2009).
2. World Health Organization. Antimicrobial resistance: global report on surveillance. WHO, Geneva (2014).
3. Witte, W. Medical consequences of antibiotic use in agriculture. Science 279, 996-997 (1998).
4. Ferber, D. Superbugs on the hoof? Science 288, 792-794 (2000).
5. Silver, L. L. Challenges of Antibacterial Discovery. ClinMicrobiol Rev. 24, 71-109 (2011).
6. Delcour, A. H. Outer membrane permeability and antibiotic resistance. BiochimBiophysActa. 1794, 808-816 (2009).
7. Wang, Y., Venter. H. & Ma, S. Efflux Pump Inhibitors: A Novel Approach to Combat Efflux-Mediated Drug Resistance in Bacteria. Curr Drug Targets. 17, 702-719 (2016).
8. Sun, J., Deng, Z. & Yan, A. Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitations. BiochemBiophys Res Commun. 17, 254-267 (2014).
9. Peeters, E., Nelis, H. J. & Coenye, T. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderiacepacia complex bacteria. J AntimicrobChemother 64, 801-809 (2009).
10. Lewis, K. Multidrug tolerance of biofilms and persister cells. Curr Top MicrobiolImmunol 322, 107-131 (2008).
11. Lebeaux, D., Ghigo, J. M. & Beloin, C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev. 78, 510-543 (2014).
12. Van Acker, H., Van Dijck, P. & Coenye, T. Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms. Trends Microbiol. 22, 326-333 (2014).
13. Michel, J. B. et al. Drug interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci USA 105, 14918-14923 (2008).
14. Hegreness, M. et al. Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci USA 105, 13977-13981 (2008).
15. Bansal, S. et al. 3,4-dimethoxyphenyl bis-benzimidazole, a novel DNA topoisomerase inhibitor that preferentially targets Escherichia coli topoisomerase I. J Antimicrob Chemother. 67, 2882-2891 (2012).
16. Tse-Dinh, Y. C. Bacterial topoisomerase I as a target for discovery of antibacterial compounds. Nucleic Acids Res. 37, 731-737 (2009).
17. Nimesh, H. et al. Synthesis and biological evaluation of novel bisbenzimidazoles as Escherichia coli topoisomerase IA inhibitors and potential antibacterial agents. J Med Chem. 26, 5238-5257 (2014).
18. Rice, L. B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 197, 1079-1081 (2008).
19. Boucher, H. W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 48, 1-12 (2009).
20. Pendleton, J. N., Gorman, S. P. & Gilmore, B. F. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti Infect. Ther. 11, 297-308 (2013
21. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement, M100-S24 (2014).
22. Nikaido, H. & Pag?s, J. M. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev. 36, 340-363 (2012).
23. Balganesh, M., Dinesh, N., Sharma, S. et al. Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother. 56, 2643-51 (2012).
24. Park, J. W., Lee, S. Y., Yang, J. Y. et al. Effect of carbonyl cyanide m-chlorophenylhydrazone (CCCP) on the dimerization of lipoprotein lipase. BiochimBiophysActa. 1344, 132-8 (1997).
25. Mahamoud, A., Chevalier, J., Alibert-Franco, S. et al. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J AntimicrobChemother. 59, 1223-9 (2007).
26. Van Bambeke, F., Pag?s, J.-M. & Lee, V. J. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat Antiinfect Drug Discov. 1, 157-75 (2006).
27. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis. 15, 561-565 (2002).
28. Davidson, R. et al. Resistance to levofloxacin and failure of treatment of Pneumococcal pneumonia. N Engl J Med. 7, 747-750 (2002).
29. Sieradzki, K. et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl. J. Med. 18, 517-523 (1999).
30. Brauner, A. et al. Distinguishing between resistance tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 15, 320-330 (2016).
31. Clinical Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard. 9 ed. Wayne, PA, USA, CLSI (2012).
32. Reimer, L. G., Stratton, C. W. & Reller, L. B. Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum. Antimicrob Agents Chemother. 19, 1050-1055 (1981).
33. Gullberg, E. et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoSPathog. 7, e1002158 (2011).
34. Tse-Dinh, Y. C. & Wang, J. C. Complete nucleotide sequence of the topA gene encoding Escherichia coli DNA topoisomerase I. J. Mol. Biol. 5, 321-331 (1986).
35. Viveiros, M. et al. Antibiotic stress, genetic response and altered permeability of E. coli. PLoS One. 11, e365 (2007).
36. Coldham, N. G. et al. A 96-well plate fluorescence assay for assessment of cellular permeability and active efflux in Salmonella entericaserovar Typhimurium and Escherichia coli. J Antimicrob. Chemotherapy. 65, 1655-1663 (2010).
37. Dwyer, D. J. et al. Antibiotic-Induced Bacterial Cell Death Exhibits Physiological and Biochemical Hallmarks of Apoptosis. Molecular Cell, 46, 561-572 (2012).
38. Stiefel, P. et al. Critical aspects of using bacterial cell viability assays with the fluorophores SYTO9 and propidium iodide. BMC Microbiol. 15, 1-9 (2015).
39. Bajaksouzian, S., Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother. 40, 1973-1976 (1996).
40. Chin, N., Weitzman, I. & Della-Latta, P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother. 41, 850-852 (1997).
41. Bajaksouzian, S. et al. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother. 40, 1973-1976 (1996
42. National committee for Clinical Laboratory Standards (NCCLS). Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA. (1999).
43. Mu, H. et al. Potent Antibacterial Nanoparticles against Biofilm and Intracellular Bacteria. Sci Rep. 5, 18877 (2016).
44. Luca, V., Stringaro, A., Colone, M., Pini, A. & Mangoni, M. L. Esculentin (1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell. Mol. Life Sci. 70, 2773-2786 (2013).
45. Franken, N. A., Rodermond, H. M., Stap, J., Haveman, J. & van Bree, C. Clonogenic assay of cells in vitro. Nat Protoc. 1, 2315-9 (2006).
46. Zeidler, U. et al. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J Antimicrob. Chemother. 68, 1285-1296 (2013).
47. Cirioni, O. et al. S-thanatin in vitro prevents colistin resistance and improves its efficacy in an animal model of Pseudomonas aeruginosa sepsis. Peptides 32, 697-701 (2011